TRDA · Entrada Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875.0K | - | $1.61M | $1.95M | $20.56M | - | $19.57M | $94.69M | $59.12M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.05M | - | $38.36M | $37.88M | $32.07M | - | $31.26M | $32.03M | $28.61M | - |
| SG&A | $10.12M | - | $10.30M | $10.92M | $10.27M | - | $9.97M | $9.24M | $9.40M | - |
| Total Operating Expenses | $43.18M | - | $48.66M | $48.80M | $42.35M | - | $41.23M | $41.27M | $38.01M | - |
| D&A | $805.0K | - | $1.20M | $1.10M | $946.0K | - | $900.0K | $900.0K | $934.0K | - |
| Operating Income | ($42.30M) | - | ($47.05M) | ($46.85M) | ($21.79M) | - | ($21.66M) | $53.42M | $21.11M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $38.0K | - | $654.0K | $178.0K | $0 | - | ($1.86M) | $2.76M | $1.83M | - |
| Net Income | ($39.72M) | - | ($44.13M) | ($43.10M) | ($17.35M) | - | ($14.03M) | $55.03M | $23.50M | - |
| EPS - Basic | ($0.95) | - | ($1.06) | ($1.04) | ($0.42) | - | ($0.35) | $1.61 | $0.70 | - |
| EPS - Diluted | ($0.95) | - | ($1.06) | ($1.04) | ($0.42) | - | ($0.35) | $1.55 | $0.68 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $76.44M | $90.39M | $93.29M | $72.48M | $67.84M | $101.21M | $78.05M | $185.25M | $68.44M | $67.60M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.93M | $2.29M | $3.17M | $1.86M | $2.19M | $4.26M | $1.29M | $1.64M | $2.53M | $3.28M |
| Current Assets | $266.87M | $306.25M | $338.26M | $369.15M | $403.19M | $440.04M | $465.33M | $489.54M | $414.17M | $369.77M |
| Total Assets | $335.52M | $377.38M | $412.90M | $448.78M | $486.48M | $526.32M | $554.59M | $581.96M | $510.84M | $469.19M |
| Current Liabilities | $19.20M | $24.45M | $24.02M | $19.80M | $18.43M | $39.48M | $70.60M | $85.81M | $173.94M | $158.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $64.66M | $71.25M | $72.18M | $69.28M | $69.22M | $97.64M | $132.14M | $152.04M | $241.48M | $226.83M |
| Stockholders' Equity | $270.85M | $306.13M | $340.72M | $379.50M | $417.26M | $428.68M | $422.45M | $429.93M | $269.37M | $242.36M |
| Retained Earnings | ($312.81M) | ($273.09M) | ($233.93M) | ($189.80M) | ($146.69M) | ($129.34M) | ($130.47M) | ($116.44M) | ($171.47M) | ($194.97M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($41.70M) | - | - | - | ($38.51M) | - | - | - | ($25.52M) | - |
| Investing Cash Flow | $26.99M | - | - | - | $4.78M | - | - | - | $26.15M | - |
| Financing Cash Flow | $100.0K | - | - | - | $350.0K | - | - | - | $206.0K | - |
| CapEx | $44.0K | - | - | - | $1.14M | - | - | - | $838.0K | - |
| Free Cash Flow | ($41.74M) | - | - | - | ($39.65M) | - | - | - | ($26.36M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -4834.6% | - | -2915.2% | -2402.5% | -106.0% | - | -110.7% | 56.4% | 35.7% | - |
| EBITDA margin | -4742.6% | - | -2840.8% | -2346.1% | -101.4% | - | -106.1% | 57.4% | 37.3% | - |
| Net margin | -4539.1% | - | -2734.4% | -2210.4% | -84.4% | - | -71.7% | 58.1% | 39.7% | - |
| Free cash flow margin | -4770.2% | - | - | - | -192.9% | - | - | - | -44.6% | - |
| FCF / Net income | 1.05 | - | - | - | 2.29 | - | - | - | -1.12 | - |
| R&D / Revenue | 3777.6% | - | 2376.8% | 1942.4% | 156.0% | - | 159.7% | 33.8% | 48.4% | - |
| SG&A / Revenue | 1157.0% | - | 638.4% | 560.1% | 50.0% | - | 51.0% | 9.8% | 15.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | 4.8% | 7.2% | - |
| Return on assets | -11.8% | - | -10.7% | -9.6% | -3.6% | - | -2.5% | 9.5% | 4.6% | - |
| Return on equity | -14.7% | - | -13.0% | -11.4% | -4.2% | - | -3.3% | 12.8% | 8.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 13.90 | 12.53 | 14.08 | 18.64 | 21.88 | 11.15 | 6.59 | 5.70 | 2.38 | 2.33 |
| Quick ratio | 13.90 | 12.53 | 14.08 | 18.64 | 21.88 | 11.15 | 6.59 | 5.70 | 2.38 | 2.33 |
| Cash ratio | 3.98 | 3.70 | 3.88 | 3.66 | 3.68 | 2.56 | 1.11 | 2.16 | 0.39 | 0.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.24 | 1.23 | 1.21 | 1.18 | 1.17 | 1.23 | 1.31 | 1.35 | 1.90 | 1.94 |
| Liabilities / Assets | 0.19 | 0.19 | 0.17 | 0.15 | 0.14 | 0.19 | 0.24 | 0.26 | 0.47 | 0.48 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.04 | - | 0.04 | 0.16 | 0.12 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | 9.2x | 20.8x | - |
| P / B | 1.9x | - | 0.7x | 0.7x | 0.9x | - | 1.5x | 1.2x | 1.8x | - |
| P / S | 603.4x | - | 149.0x | 142.5x | 18.1x | - | 33.2x | 5.3x | 8.3x | - |
| EV / EBITDA | - | - | - | - | - | - | - | 5.9x | 19.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -95.7% | - | -91.8% | -97.9% | -65.2% | - | - | - | 134.0% | - |
| Revenue CAGR (3y) | -67.4% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -94.1% | - | -117.2% | - | - | - | - | - | - | - |
| Net income growth (YoY) | -128.9% | - | -214.5% | - | - | - | - | - | - | - |
| EPS growth (YoY) | -126.2% | - | -202.9% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -5.3% | - | - | - | -50.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -35.1% | -28.6% | -19.3% | -11.7% | 54.9% | 76.9% | 71.3% | 107.8% | 17.3% | 14.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$25.42M totalReportable Segment$25.42M · 100.0%
Product / service
$25.50M totalRecognition Of Upfront And Milestone Payments$20.30M · 79.6%
Collaboration Service Revenue$5.20M · 20.4%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Entrada Therapeutics against the 5 most active filers in the same SIC group.